16. Clinical value of a novel culture medium for simultaneous growth of hematopoietic cell lineages for cytogenetic analysis

      Hematopoietic malignancies, a leading cause of death in the US, derive from lymphoid (T-cell, B-cell, and plasma cell) and myeloid cell lines. In most clinical cases, the cytogeneticist selects the hematopoietic cell line(s) to culture based upon the oncologist's clinical suspicion, and the cultures are initiated immediately after specimen receipt. Present culture media for a given cell lineage require specific mitogens or growth factors to stimulate cell growth, which limits the ability to accurately determine disease status if the incorrect cell type is initially chosen. If the incorrect lineage is selected, the clinical impact could lead to poor correlation between karyotyping and FISH or flow cytometry/morphology. A false negative result and/or delayed diagnosis may occur.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect